{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:35:02Z","timestamp":1781782502583,"version":"3.54.5"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.critrevonc.2019.03.013","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T11:14:20Z","timestamp":1554117260000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Current management of neuroblastoma and future direction"],"prefix":"10.1016","volume":"138","author":[{"given":"Elizabeth R.","family":"Pastor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaker A.","family":"Mousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.03.013_bib0005","series-title":"Childhood and Adolescent Cancer","author":"American Cancer Society","year":"2018"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0010","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1158\/1078-0432.CCR-13-0680","article-title":"New strategies in neuroblastoma: therapeutic targeting of MYCN and ALK","volume":"19","author":"Barone","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0015","first-page":"226","article-title":"Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma","volume":"4","author":"Bassiri","year":"2015","journal-title":"Transl. Pediatr."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0020","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ccell.2014.09.019","article-title":"ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma","volume":"26","author":"Bresler","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ccr.2013.05.005","article-title":"Small molecule inhibitors of Aurora-A induce proteasomal degradation of N-Myc in childhood neuroblastoma","volume":"24","author":"Brockmann","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0030","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1158\/1078-0432.CCR-08-1815","article-title":"Trk receptor expression and inhibition in neuroblastomas","volume":"15","author":"Brodeur","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1517\/14728222.2014.867946","article-title":"Therapeutic targets for neuroblastomas","volume":"18","author":"Brodeur","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0040","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/carcin\/bgs380","article-title":"Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility","volume":"34","author":"Capasso","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0045","author":"Children\u2019s Oncology Group"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/ijc.30479","article-title":"Implantable chemotherapy-loaded silk protein materials for neuroblastoma treatment","volume":"140","author":"Coburn","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0055","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The international neuroblastoma risk group (INRG) classification system: an INRG task force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00280-014-2627-1","article-title":"TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts","volume":"75","author":"Croucher","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.sempedsurg.2011.10.009","article-title":"Neuroblastoma","volume":"21","author":"Davidoff","year":"2012","journal-title":"Semin. Pediatr. Surg."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0070","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two Phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0075","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.2015.65.4889","article-title":"Phase I study of the Aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (new approaches to neuroblastoma therapy) trial","volume":"34","author":"DuBois","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0080","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1535-7163.MCT-11-0333","article-title":"The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo","volume":"10","author":"Faisal","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0085","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1158\/1078-0432.CCR-17-0379","article-title":"A pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18k322a) with chemotherapy and natural killer cells in children with recurrent\/refractory neuroblastoma","volume":"23","author":"Federico","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0090","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.neo.2018.08.002","article-title":"Dual BRD4 and AURKA inhibition is synergistic against MYCN-amplified and nonamplified neuroblastoma","volume":"20","author":"Felgenhauer","year":"2018","journal-title":"Neoplasia"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0095","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2967\/jnumed.110.085100","article-title":"177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma","volume":"52","author":"Gains","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0100","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/pbc.22913","article-title":"Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma","volume":"56","author":"Georgantzi","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0105","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1242\/dmm.024448","article-title":"The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN","volume":"9","author":"Guan","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0110","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-15-1449","article-title":"Targeting MYCN-driven transcription by BET-bromodomain inhibition","volume":"22","author":"Henssen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0115","doi-asserted-by":"crossref","first-page":"9735","DOI":"10.1158\/0008-5472.CAN-07-6866","article-title":"ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma","volume":"68","author":"Hogarty","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/2159-8290.CD-15-1056","article-title":"The ALK\/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma","volume":"6","author":"Infarinato","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0125","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.canlet.2016.01.018","article-title":"Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model","volume":"372","author":"Iyer","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.phrs.2018.02.023","article-title":"Molecular mechanisms and therapeutic targets in neuroblastoma","volume":"131","author":"Johnsen","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0135","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7394268","article-title":"Neuroblastoma origin and therapeutic targets for immunotherapy","volume":"2018","author":"Kholodenko","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.2910390113","article-title":"Shedding of GD2 ganglioside by human neuroblastoma","volume":"39","author":"Ladisch","year":"1987","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0145","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.surg.2015.04.017","article-title":"Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma","volume":"158","author":"Lee","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0150","article-title":"Alpha-difluoromethylornithine, an irreversible inhibitor of polyamine biosynthesis, as a therapeutic strategy against hyperproliferative and infectious diseases","volume":"6","author":"LoGiudice","year":"2018","journal-title":"Med. Sci. (Basel)"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0155","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0160","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMra0804577","article-title":"Recent advances in neuroblastoma","volume":"362","author":"Maris","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0165","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(07)60983-0","article-title":"Neuroblastoma","volume":"369","author":"Maris","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0170","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children\u2019s Cancer Group","volume":"341","author":"Matthay","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0175","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-11-1939","article-title":"Promising therapeutic targets in neuroblastoma","volume":"18","author":"Matthay","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0180","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Mertz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0185","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2008.16.6876","article-title":"The international neuroblastoma risk group (INRG) staging system: an INRG task force report","volume":"27","author":"Monclair","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0190","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27556","article-title":"The challenge of defining \"ultra-high-risk\" neuroblastoma","volume":"66","author":"Morgenstern","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0195","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/1078-0432.CCR-14-1100","article-title":"Anaplastic lymphoma kinase as a cancer target in pediatric malignancies","volume":"22","author":"Mosse","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0200","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1158\/1078-0432.CCR-11-3251","article-title":"Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase a: a Children\u2019s Oncology Group Phase I Consortium study","volume":"18","author":"Mosse","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0205","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1200\/JCO.2013.50.4423","article-title":"Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14. 18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma","volume":"32","author":"Navid","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0210","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3389\/fimmu.2018.01355","article-title":"A comprehensive safety trial of chimeric antibody 14.18 with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children\u2019s Oncology Group Study ANBL0931","volume":"9","author":"Ozkaynak","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0215","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1200\/JCO.2014.59.4648","article-title":"Advances in risk classification and treatment strategies for neuroblastoma","volume":"33","author":"Pinto","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0220","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/1947601910377494","article-title":"Therapeutic targeting of Myc","volume":"1","author":"Prochownik","year":"2010","journal-title":"Genes Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0225","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","article-title":"Targeting MYCN in neuroblastoma by BET bromodomain inhibition","volume":"3","author":"Puissant","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0230","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14737140.2017.1364995","article-title":"Anti-GD2 immunotherapy for neuroblastoma","volume":"17","author":"Sait","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127246","article-title":"A Phase I trial of DFMO targeting polyamine addiction in patients with relapsed\/refractory neuroblastoma","volume":"10","author":"Saulnier Sholler","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0240","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1158\/2159-8290.CD-13-0018","article-title":"Targeting MYCN: a good BET for improving neuroblastoma therapy?","volume":"3","author":"Schnepp","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0245","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1158\/1535-7163.MCT-08-0857","article-title":"Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma","volume":"8","author":"Shang","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"68","key":"10.1016\/j.critrevonc.2019.03.013_bib0250","first-page":"7","article-title":"Cancer statistics, 2018","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0255","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0260","article-title":"Targeted radiotherapy of neuroblastoma: future directions","volume":"4","author":"Tesson","year":"2017","journal-title":"Integr. Cancer Sci. Ther."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0265","doi-asserted-by":"crossref","first-page":"29082","DOI":"10.18632\/oncotarget.25607","article-title":"An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with 177Lu-DOTATATE for the treatment of neuroblastoma","volume":"9","author":"Tesson","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0270","doi-asserted-by":"crossref","first-page":"19423","DOI":"10.1038\/srep19423","article-title":"Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0275","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2011.11.031","article-title":"Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers","volume":"159","author":"Wolinsky","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0280","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1002\/cam4.1634","article-title":"ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid","volume":"7","author":"Wu","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0285","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbmt.2014.12.008","article-title":"131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study","volume":"21","author":"Yanik","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0290","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jconrel.2018.07.002","article-title":"In vitro and in vivo evaluation of etoposide \u2013 silk wafers for neuroblastoma treatment","volume":"285","author":"Yavuz","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0295","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.03.013_bib0300","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9481276","article-title":"Correlation of somatostatin receptor-2 expression with Gallium-68-DOTA-TATE uptake in neuroblastoma xenograft models","volume":"2017","author":"Zhang","year":"2017","journal-title":"Contrast Media Mol. Imaging"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818305122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818305122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:28:13Z","timestamp":1760902093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818305122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":60,"alternative-id":["S1040842818305122"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.03.013","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current management of neuroblastoma and future direction","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}